Current treatments can slow muscle damage ... PTPN1/2 inhibition promotes muscle stem cell differentiation in Duchenne muscular dystrophy. Life Sci Alliance. 2025;8(1):e202402831. doi: ...

Researchers at the Experimental and Clinical Research Center in Berlin are developing a targeted treatment for ... in patients with muscular dystrophy diseases. The dysferlin protein is primarily ...

Ips Heart Inc. has been awarded orphan drug designation by the FDA for its GIVI-MPC stem cell therapy for Becker muscular dystrophy. GIVI-MPC has the unique ability to create new muscle with full ...

IPS HEART has now shown GIVI-MPCs create new human muscle with full length human dystrophin in dystrophic pigs, young and extremely aged Duchenne Muscular Dystrophy (DMD) mice and in a sarcopenia ...

Stem cell therapy is yet to prove effective for muscular dystrophy and has not been approved on the NHS so Celine's parents, Lottie and Charlie, have instead raised £86,000 to fund the treatment ...

The dysferlin protein is primarily responsible for repairing cell membranes ... successfully removed muscle stem cells from two patients with limb-girdle muscular dystrophy, corrected the genetic ...

(RTTNews) - Sarepta Therapeutics, Inc. (SRPT) Monday reported positive topline results from Part 2 of the Phase 3 study, dubbed EMBARK, of its gene therapy Elevidys approved for the treatment of ...

An Irish woman has launched a fundraiser to help raise money for medical treatment for her seven-year-old son. Una Ennis' son ...

HOUSTON, January 13, 2025--(BUSINESS WIRE)--IPS HEART has been awarded Orphan Drug Designation (ODD) by the FDA for GIVI-MPCs based on its unique ability to create new muscle with full length ...